We are a RNA therapeutics company using our proprietary, next-generation silicon stabilized hybrid lipid nanoparticles (sshNLP) to address unmet medical needs in the therapeutically neglected field of Genetic Skeletal Disorders. Built upon a decade of research and patented technological innovation, our BIO-COURIER® platform is changing the way therapeutic molecules target disease helping to make tomorrow’s medicines a reality.
Location: United Kingdom, England, Guildford
Employees: 11-50
Total raised: $17.5M
Founded date: 2008
Investors 2
| Date | Name | Website |
| - | Vickers Ve... | vickersven... |
| - | Clarendon ... | clarendon-... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 27.11.2020 | - | $13.2M | Vickers Ve... |
| 31.05.2018 | - | $4.3M | - |
Mentions in press and media 5
| Date | Title | Description |
| 17.07.2023 | SiSaf Appoints Nikos Tzagkarakis in the New Role of Chief AI Officer | RNA delivery and therapeutics company SiSaf Ltd announces that it has appointed Nikos Tzagkarakis in the newly created role of Chief A.I. Officer. AiThority Interview Insights: How to Get Started with Prompt Engineering in Generative AI Pro... |
| 27.11.2020 | SG’s Vickers Venture leads $13.2m funding in UK biotech startup SiSaf | Singapore-based venture capital firm Vickers Venture Partners has led the $13.2-million Series B funding in SiSaf, a UK-headquartered biotech startup that develops drugs using Bio-Courier technology, according to an announcement. The fundin... |
| 27.11.2020 | SG’s Vickers Venture leads $13.2m funding in UK biotech startup SiSaf | Premium Singapore-based venture capital firm Vickers Venture Partners has led the $13.2-million Series B funding in SiSaf, a UK-headquartered biotech startup that develops drugs using Bio-Courier technology, according to an announcement. Co... |
| 31.05.2018 | SiSaf Closes $4.3M Series A2 Interim Funding Round | SiSaf, a Belfast and Guildford, UK-based biopharmaceutical company, closed a $4.3m A2 Interim funding round. The round was led by Vickers Venture Partners, with participation from Invest NI and Innovation Ulster Limited. Led by Founder and ... |
| 20.09.2016 | Singapore: Vickers Venture leads $3.5m Series A into SiSaf | Premium Vickers Venture Partners, a venture capital (VC) firm with a global footprint, has announced a Series A investment of US$3.5 million along with Exen Capital into the next-gen silicon nanotechnology drug delivery company SiSaf. Inves... |